FourThought Financial LLC Increases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

FourThought Financial LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 10.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 354 shares of the company’s stock after acquiring an additional 33 shares during the quarter. FourThought Financial LLC’s holdings in IDEXX Laboratories were worth $115,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of IDXX. Panagora Asset Management Inc. increased its position in shares of IDEXX Laboratories by 50.3% during the first quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock worth $1,768,000 after acquiring an additional 1,081 shares during the last quarter. Raymond James Trust N.A. grew its stake in IDEXX Laboratories by 26.8% in the first quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock worth $888,000 after purchasing an additional 343 shares in the last quarter. Cetera Investment Advisers grew its stake in IDEXX Laboratories by 77.1% in the first quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock worth $2,010,000 after purchasing an additional 1,600 shares in the last quarter. Moors & Cabot Inc. grew its stake in IDEXX Laboratories by 3.0% in the first quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock worth $961,000 after purchasing an additional 52 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in IDEXX Laboratories by 15.6% in the first quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock worth $543,000 after purchasing an additional 134 shares in the last quarter. 87.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on IDXX shares. StockNews.com started coverage on IDEXX Laboratories in a research note on Thursday. They issued a “buy” rating for the company. TheStreet upgraded IDEXX Laboratories from a “c+” rating to a “b-” rating in a research note on Friday, November 25th. The Goldman Sachs Group lifted their price target on IDEXX Laboratories from $465.00 to $530.00 and gave the stock a “buy” rating in a research note on Wednesday, January 25th. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $525.00 to $550.00 and gave the company an “overweight” rating in a research note on Tuesday, February 7th. Finally, Atlantic Securities lifted their target price on IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research note on Tuesday, February 7th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $514.75.

Insider Buying and Selling

In related news, SVP Kathy V. Turner sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $505.04, for a total transaction of $505,040.00. Following the sale, the senior vice president now owns 6,941 shares of the company’s stock, valued at $3,505,482.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Kathy V. Turner sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of $505.04, for a total transaction of $505,040.00. Following the sale, the senior vice president now owns 6,941 shares of the company’s stock, valued at $3,505,482.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Kathy V. Turner sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total value of $1,009,180.00. Following the sale, the senior vice president now directly owns 7,380 shares in the company, valued at approximately $3,723,874.20. The disclosure for this sale can be found here. 2.06% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $471.36 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 1.14. The stock has a 50 day simple moving average of $481.48 and a 200-day simple moving average of $414.74. The company has a market cap of $39.08 billion, a PE ratio of 58.70, a P/E/G ratio of 2.74 and a beta of 1.18. IDEXX Laboratories, Inc. has a 12-month low of $317.06 and a 12-month high of $560.92.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last issued its quarterly earnings data on Monday, February 6th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.13. The business had revenue of $828.60 million during the quarter, compared to the consensus estimate of $820.91 million. IDEXX Laboratories had a return on equity of 124.51% and a net margin of 20.17%. The business’s revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.89 earnings per share. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 9.58 EPS for the current year.

IDEXX Laboratories Company Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.